Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
The classification of Prostate Cancer Diagnostics includes Tumor Biomarker Tests, Imaging, Biopsy and other, and most of Prostate Cancer Diagnostics use the method of Biopsy, the proportion of Biopsy in 2017 is about 44.65%.
Prostate Cancer Diagnostics is widely used for the people with Prostate Cancer, The most proportion of Prostate Cancer Diagnostics is used for people with the age between 55 and 75, and the proportion is about 70.24% in 2017.
North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49.84% in 2017. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28% in 2017.
Market Analysis and Insights: Global Prostate Cancer Diagnostics Market
The global Prostate Cancer Diagnostics market was valued at US$ 13430 in 2020 and will reach US$ 20490 million by the end of 2027, growing at a CAGR of 7.3% during 2022-2027.
Global Prostate Cancer Diagnostics Scope and Market Size
The global Prostate Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segment by Application
age Below 55
age 55-75
age Above 75
The Prostate Cancer Diagnostics market is analysed and market size information is provided by regions (countries). Segment by Application, the Prostate Cancer Diagnostics market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Genomic Health
Abbott
OPKO
Siemens Healthcare
DiaSorin
BioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics
The classification of Prostate Cancer Diagnostics includes Tumor Biomarker Tests, Imaging, Biopsy and other, and most of Prostate Cancer Diagnostics use the method of Biopsy, the proportion of Biopsy in 2017 is about 44.65%.
Prostate Cancer Diagnostics is widely used for the people with Prostate Cancer, The most proportion of Prostate Cancer Diagnostics is used for people with the age between 55 and 75, and the proportion is about 70.24% in 2017.
North America region is the largest region of Prostate Cancer Diagnostics, with a revenue market share nearly 49.84% in 2017. Europe is the second region of Prostate Cancer Diagnostics, enjoying revenue market share nearly 28% in 2017.
Market Analysis and Insights: Global Prostate Cancer Diagnostics Market
The global Prostate Cancer Diagnostics market was valued at US$ 13430 in 2020 and will reach US$ 20490 million by the end of 2027, growing at a CAGR of 7.3% during 2022-2027.
Global Prostate Cancer Diagnostics Scope and Market Size
The global Prostate Cancer Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Tumor Biomarker Tests
Imaging
Biopsy
Other
Segment by Application
age Below 55
age 55-75
age Above 75
The Prostate Cancer Diagnostics market is analysed and market size information is provided by regions (countries). Segment by Application, the Prostate Cancer Diagnostics market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
Genomic Health
Abbott
OPKO
Siemens Healthcare
DiaSorin
BioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
